Initial Treatment Approach for Infrahilar Infiltrates

Diagnostic Approach

The American College of Oncology recommends obtaining high-resolution or multislice CT scan of the chest as conventional radiographs may miss significant pathology in up to 50% of cases 1
CT findings can help distinguish between bacterial, fungal, and viral etiologies, with nodular or cavitary lesions suggesting invasive filamentous fungal infection 1
Diffuse bilateral perihilar infiltrates may indicate Pneumocystis pneumonia (PcP) 1
Consolidation patterns often suggest bacterial pneumonia 1
Bronchoscopy with bronchoalveolar lavage (BAL) should be considered to identify specific pathogens before starting antimicrobial therapy, but treatment should not be delayed if the patient is clinically unstable 1, 2

The American College of Oncology recommends starting with an antipseudomonal β-lactam such as piperacillin-tazobactam, ceftazidime, imipenem/cilastatin, meropenem, or cefepime for immunocompetent patients 2
An aminoglycoside should be considered if Pseudomonas aeruginosa is suspected or confirmed 2
For patients who cannot tolerate aminoglycosides, the antipseudomonal β-lactam should be combined with ciprofloxacin 2
For immunocompromised patients, broad-spectrum antibiotics should be started, with empiric antifungal therapy added if the patient has been febrile for >4-6 days despite antibacterial therapy, or if CT scan shows halo sign, air-crescent sign, or nodular lesions 2, 3
Trimethoprim-sulfamethoxazole (TMP/SMX) should be considered if PcP is suspected, especially in patients with diffuse bilateral perihilar infiltrates, rapid rise in serum lactate dehydrogenase, or history of immunosuppression or HIV 1, 2, 4

For neutropenic patients, daily clinical assessment of treatment response should be performed, and imaging studies should not be repeated earlier than 7 days after starting treatment unless clinical deterioration occurs 2
For patients with Coccidioidomycosis, amphotericin B should be started if significant hypoxia is present, and oral azole antifungal therapy should be transitioned to after clinical improvement for at least 1 year 5

Clinical response should be assessed daily, and if no improvement is seen after 48 hours but the patient is clinically stable, initial therapy should be continued 2, 3
If the patient is clinically unstable after 48 hours, antimicrobial coverage should be broadened and infectious disease consultation should be sought 3
A repeat CT scan should be performed after 7 days of treatment if clinical improvement is lacking 2

Delaying antimicrobial therapy while waiting for diagnostic results in unstable patients should be avoided 1, 2
Increasing volume of pulmonary infiltrates during the first week of antifungal therapy should not be misinterpreted as treatment failure 1
Overreliance on conventional chest radiographs, which may miss significant pathology, should be avoided 1